Candida species: Current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options
Nenhuma Miniatura disponível
Data
2013-01-01
Autores
Sardi, J. C. O. [UNESP]
Scorzoni, L. [UNESP]
Bernardi, T. [UNESP]
Fusco-Almeida, A. M. [UNESP]
Mendes-Giannini, Maria José Soares [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
The incidence of fungal infections has increased significantly, so contributing to morbidity and mortality. This is caused by an increase in antimicrobial resistance and the restricted number of antifungal drugs, which retain many side effects. Candida species are major human fungal pathogens that cause both mucosal and deep tissue infections. Recent evidence suggests that the majority of infections produced by this pathogen are associated with biofilm growth. Biofilms are biological communities with a high degree of organization, in which micro-organisms form structured, coordinated and functional communities. These biological communities are embedded in a self-created extracellular matrix. Biofilm production is also associated with a high level of antimicrobial resistance of the associated organisms. The ability of Candida species to form drugresistant biofilms is an important factor in their contribution to human disease. The study of plants as an alternative to other forms of drug discovery has attracted great attention because, according to the World Health Organization, these would be the best sources for obtaining a wide variety of drugs and could benefit a large population. Furthermore, silver nanoparticles, antibodies and photodynamic inactivation have also been used with good results. This article presents a brief review of the literature regarding the epidemiology of Candida species, as well as their pathogenicity and ability to form biofilms, the antifungal activity of natural products and other therapeutic options. © 2013 SGM.
Descrição
Palavras-chave
adhesin, amphotericin B, anidulafungin, antifungal agent, caspofungin, cinnamon extract, Coriandrum sativum extract, echinocandin, essential oil, fluconazole, flucytosine, itraconazole, ketoconazole, micafungin, miconazole, nystatin, posaconazole, silver nanoparticle, terconazole, usnic acid, voriconazole, antifungal activity, artificial ventilation, biofilm, Candida, Candida albicans, Candida dubliniensis, Candida glabrata, Candida metapsilosis, Candida orthopsilosis, Candida parapsilosis, Candida rugosa, Candida tropicalis, candidemia, candidiasis, Clavispora lusitaniae, critically ill patient, extracellular matrix, fungal colonization, fungal community, fungal virulence, fungus isolation, hemodialysis, human, incidence, intensive care unit, intestine flora, medical device, mononuclear phagocyte, neutrophil, nonhuman, photodynamics, Pichia guilliermondii, priority journal, review, systemic mycosis, Antifungal Agents, Biofilms, Biological Agents, Candidiasis, Humans
Como citar
Journal of Medical Microbiology, v. 62, n. PART1, p. 10-24, 2013.